case report as May-Thurner or Cockett's syndrome) [3, 4] . In these patients a successful thrombolytic therapy combined with implantation of a venous stent can result in a very good long-term clinical outcome, and these patients can return to work and their normal everyday activities [4, 5] .
case report
The 37-year-old female patient with obesity [102 kg; body mass index (BMI): 37.9), hyperlipidaemia and glucose intolerance, with 18-day history of left lower leg DVT manifesting with persistent and severe oedema, was admitted to the hospital due to dyspnoea. Because of DVT this patient was previously admitted to another hospital and discharged with the recommendation of anticoagulation with rivaroxaban 15 mg twice a day.
Potential risk factors of thrombosis in this case comprised oral contraceptives taken during the last 3 months before the event. Mild anaemia (haemoglobin: 10.2 g/dl) was the only laboratory abnormality revealed on admission. Clinical probability of pulmonary embolism (PE) rated by both the Wells' criteria and the Revised Gene- Computed tomography (CT) angiography of the veins of lower extremities and pelvis, which was performed on the day of admission, revealed radiographic signs of thrombosis (dilatation of the vein with lack of enhancement of its lumen) of the left femoral vein, pelvic veins and the inferior vena cava up to the level of L3-L4 (Fig. 1) . Therefore, we also performed CT angiography of the pulmonary arteries. This study detected the signs of PE in the lobular, segmental and subsegmental arteries. Based on the clinical status of the patient and the Pulmonary Embolism Severity Index (PESI) we estimated the probability of early 30-day mortality as low and considered our patient as low-risk according to the PESI score [6] , which meant that according to current guidelines PE should be managed conservatively. After discontinuation of rivaroxaban and 48-hour intravenous infusion of heparin, the Option ELITE retrievable vena cava filter (Argon Medical Devices, Plano, TX, USA) was temporarily implanted into the inferior vena cava via the right jugular vein (Fig. 2) . Then, after cannulation under ultrasound guidance of the left popliteal vein, a standard 6F 11 cm long catheter sheath was inserted over the 0.035" guidewire. Under fluoroscopic guidance, we navigated through the obstruction of femoral and iliac veins using a short loop made of the 0.035" 260 cm long stiff-type Terumo hydrophilic guidewire (Terumo Corp., Tokyo, Japan), which was supported by the 4F vertebral hydrophilic catheter (Cook Medical Inc., Bloomington, IN, USA). The crossing was relatively easy, except for the proximal part of the left common iliac vein, where some force was needed to enter the inferior vena cava. Then, over the guidewire we introduced the 4F Fountain thrombolysis catheter (Merit Medical Systems Inc., South Jordan, UT, USA) with the working length of the system 50 cm (Fig. 3) . Through this catheter we performed pulse-spray thrombolysis with alteplase. Firstly we injected a bolus dose of alteplase (2 mg diffused in 5 ml of saline), and then the drug was infused at a rate of 1 mg/h. In addition, infusion of unfractionated heparin was continued through the side port of the sheath located in the popliteal vein. Adjustments of heparin dosages were made to maintain activated partial thromboplastin time (APTT) values within the range of 1.5 to 2.5 times the patient's baseline control. Local thrombolysis was continues for 72 hours, under monitoring of fibrinogen concentration and platelet counts. During thrombolytic therapy, tight compression bandaging was applied from the level of the foot up to the groin. Angiography performed 24 h and 48 h after the beginning of thrombolytic treatment revealed almost complete patency of the popliteal, femoral and iliac veins. On the 3 rd day of fibrinolysis an asymptomatic haematuria was observed, but ultrasound examination of the abdomen did not reveal abnormalities. On the same day we removed the Fountain catheter and through the popliteal access we introduced the 0.014" Eagle Eye Platinum Catheter (Volcano Corp., San Diego, CA, USA) and using the Volcano s5 Imaging System (Volcano Corp., San Diego, CA, USA) we performed intravascular ultrasound (IVUS) of the veins of the left lower extremity. This examination revealed a compression of the left common iliac vein by the right common iliac artery (Fig. 4) . After predilatation of the stenotic part of the vein with the 12 × 40 mm Zelos balloon catheter (Optimed, Ettlingen, Germany), which was slowly inflated up to 12 atm (Fig. 5) , endovascular treatment was completed with implantation of the 14 × 60 mm Sinus-Obliquus hybrid venous stent (Optimed, Ettlingen, Germany) (Fig. 6 ). Angiography demonstrated a very good final result. The clinical result 3 days after stent implantation is presented in Fig. 7 . Two days after the procedure the patient was mobilised and began an intensive rehabilitation programme. Haematuria was no longer present. We started anticoagulation with acenocoumarol (dose adjusted in accordance with the INR test) and antiplatelet therapy with clopidogrel (75 mg/day). The patient was advised to wear class 2 compression hosiery. Ten days after stent implantation the patient reported severe pain of the left lumbar region and iliac fossa. Abdominal bedside ultrasonography was suggestive of retroperitoneal bleeding. Therefore, abdominal CT was performed, which confirmed the presence of retroperitoneal haematoma. The patient was administered 5 mg of vitamin K, one unit of fresh frozen plasma and 2 units of blood. Then, she was transferred to the vascular surgery department. On the following day, when coagulation parameters returned to their normal values, the patient underwent surgical exploration, the haematoma was removed, but still the source of bleeding was not found. The patient was discharged in very good clinical condition, with the recommendation of anticoagulation therapy with acenocoumarol for at least 6 months. After 3 weeks, the filter implanted into the inferior vena cava was removed. The patient returned to full work activity. The present case report deals with several aspects of the treatment for acute DVT of the pelvic, femoral and popliteal veins. According to the Polish Guidelines for Prevention and Treatment of Venous Thrombosis, published in 2012, catheter-directed thrombolytic therapy should be used in patients with a clinical history of DVT not longer than 14 days, in good general condition, with low risk of bleeding, and who consider the prevention of post-thrombotic syndrome as a priority [7, 8] . However, the aforementioned therapy can also be effective in a case of DVT that is present for 21 [9] or even 28 days [10] . The present case confirms that catheter-directed thrombolysis can be effective even 14 days after onset of the disease.
There is an increased risk of recurrent DVT in a case of stenosis of the vein, and it has been found that a 40-50% reduction of the venous lumen can result in 70% higher risk of recurrent DVT [5] . Therefore, stent implantation seems to significantly affect the long-term efficacy of the thrombolytic therapy [11] . However, the choice of a proper stent remains problematic. At the moment there are four marketed stents that are registered for venous implantations. These are: Zilver Vena (Cook Medical Inc, Bloomington, IN, USA), Wallstent (Boston Scientific Corp., Marlborough, MA, USA), Vici (Veniti, Inc., St. Louis, MO, USA) and Sinus-Venous (Optimed, Ettlingen, Germany). These stents differ in the design, radial force, and flexibility. Therefore, they should be chosen individually in order to prevent complications and obtain an optimal effect in the long run.
In this patient we decided to implant one of the newest hybrid venous stents, named Sinus-Obliquus, manufactured by Optimed. The unique oblique design of the thrombolysis complicated with late extraperitoneal bleeding Phlebological Review 2015 fig. 7 . Clinical result of the treatment: patient's legs on admission (left) and 3 days after stent implantation (right) stent combines the advantages of a closed-cell stent (high radial force) and an open-cell device (high flexibility and plasticity), thus enabling its precise positioning and good clinical efficacy. In addition, it is not necessary to extend this stent into the inferior vena cava.
The decision regarding temporary implantation of an inferior vena cava filter is also controversial. In our patient we decided to implant the filter because she had already undergone PE, there was extension of the thrombus into the inferior vena cava, and the current thromboembolic event occurred despite anticoagulation with rivaroxaban. Also, in our opinion there was a risk of PE during endovascular manoeuvres aimed at recanalisation of femoral and iliac veins. Still, the guidelines do not recommend routine filter implantation in patients managed with anticoagulants (recommendation class 1B) [7, 8, [10] [11] [12] [13] .
